phase i-ii trial induct chemotherapi carboplatin fluorouracil advanc head neck squamou cell carcinoma report ucl-oncolog group belgium eighty-thre patient median age year karnofski perform statu equal carboplatin carbo fluorouracil stage iii IV head neck squamou cell carcinoma hnscc day continu infus carbo day order maximum-toler dose mtd dose level effect associ potenti role local control patient carbo dose cours week overal primari tumor node respons complet respons CR rate primari tumor respons rate RR CR patholog complet respons pcr RR patient oropharyng tumor patient carbo equal tumor size good prognost factor RR CR pcr node RR CR grade neutropenia thrombocytopenia patient carbo patient mtd dose thirty-eight patient surgeri radiotherapi radiotherapi surgeri median follow-up month disease-fre surviv df overal complet respond other primari tumor recurr patient primari tumor pcr radiotherapi tumor control median follow-up month associ safe induct chemotherapi regimen hnscc dose carbo futur treatment abstract truncat AT word 